Last updated: 2026-10-13 23:18:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
AbCellera Biologics Inc. (ABCL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $12.61, with a market capitalization of $4.07B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.75 to $15.02. This page covers its latest market performance, valuation, price trends and company information.
$4.07B | |
$12.53 | |
$71.91 | |
$1.89 | |
$12.64 | |
3.05M | |
6.74M | |
-- | |
$15.02 | |
$2.75 | |
-- | |
-- |
AbCellera Biologics Inc. (ABCL) is trading at $12.68 in after-hours trading as of 2026-10-13 23:14:00, up 0.35% ($0.04) from the regular-session close of $12.64.
After-hours trading shows how investors are pricing ABCL after the regular session closes. The current after-hours price is near the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, AbCellera Biologics Inc. (ABCL) moved from $13.74 to $12.61, representing a decline of 8.25% ($1.13).
The stock traded between $11.89 and $14.53 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 5.94 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 80.4%
ABCL is currently trading at $12.61, placing it 80.4% of the way from its 52-week low of $2.75 to its 52-week high of $15.02. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 562 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of AbCellera Biologics Inc. (ABCL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.